All Good Things...

Despite its well-received genome-wide association scan papers, DeCode Genetics is on the brink of extinction, says Technology Review. According to the article, DeCode has spent more than $600 million, never made a profit, and has $3.7 million left as its stock hovers at 57 cents, down from $29 when the company first launched. Founder Kari Stefansson recently told investors that he is re-envisioning DeCode as a gene-based diagnostics company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.